Heather E Hoch1, Agustin Calatroni2, Joseph B West3, Andrew H Liu4, Peter J Gergen5, Rebecca S Gruchalla6, Gurjit K Khurana Hershey7, Carolyn M Kercsmar7, Haejin Kim8, Carin I Lamm9, Melanie M Makhija10, Herman E Mitchell2, Stephen J Teach11, Jeremy J Wildfire2, William W Busse12, Stanley J Szefler4. 1. Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo. Electronic address: Heather.hoch@childrenscolorado.org. 2. Rho Federal Systems Division, Chapel Hill, NC. 3. Boston University School of Medicine, Boston, Mass. 4. Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo. 5. National Institute of Allergy and Infectious Diseases, Bethesda, Md. 6. University of Texas Southwestern Medical Center, Dallas, Tex. 7. Cincinnati Children's Hospital, Cincinnati, Ohio. 8. Henry Ford Health System, Detroit, Mich. 9. Columbia University College of Physicians and Surgeons, New York, NY. 10. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill. 11. Children's National Health System, Washington, DC. 12. University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Abstract
BACKGROUND: A Seasonal Asthma Exacerbation Predictive Index (saEPI) was previously reported based on 2 prior National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium trials. OBJECTIVE: This study sought to validate the saEPI in a separate trial designed to prevent fall exacerbations with omalizumab therapy. METHODS: The saEPI and its components were analyzed to characterize those who had an asthma exacerbation during the Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations (PROSE) study. We characterized those inner-city children with and without asthma exacerbations in the fall period treated with guidelines-based therapy (GBT) in the absence and presence of omalizumab. RESULTS: A higher saEPI was associated with an exacerbation in both the GBT alone (P < .001; area under the curve, 0.76) and the GBT + omalizumab group (P < .01; area under the curve, 0.65). In the GBT group, younger age at recruitment, higher total IgE, higher blood eosinophil percentage and number, and higher treatment step were associated with those who had an exacerbation compared with those who did not. In the GBT + omalizumab group, younger age at recruitment, increased eosinophil number, recent exacerbation, and higher treatment step were also associated with those who had an exacerbation. The saEPI was associated with a high negative predictive value in both groups. CONCLUSIONS: An exacerbation in children treated with GBT with or without omalizumab was associated with a higher saEPI along with higher markers of allergic inflammation, treatment step, and a recent exacerbation. Those that exacerbated on omalizumab had similar features with the exception of some markers of allergic sensitization, indicating a need to develop better markers to predict poor response to omalizumab therapy and alternative treatment strategies for children with these risk factors. The saEPI was able to reliably predict those children unlikely to have an asthma exacerbation in both groups.
BACKGROUND: A Seasonal Asthma Exacerbation Predictive Index (saEPI) was previously reported based on 2 prior National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium trials. OBJECTIVE: This study sought to validate the saEPI in a separate trial designed to prevent fall exacerbations with omalizumab therapy. METHODS: The saEPI and its components were analyzed to characterize those who had an asthma exacerbation during the Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations (PROSE) study. We characterized those inner-city children with and without asthma exacerbations in the fall period treated with guidelines-based therapy (GBT) in the absence and presence of omalizumab. RESULTS: A higher saEPI was associated with an exacerbation in both the GBT alone (P < .001; area under the curve, 0.76) and the GBT + omalizumab group (P < .01; area under the curve, 0.65). In the GBT group, younger age at recruitment, higher total IgE, higher blood eosinophil percentage and number, and higher treatment step were associated with those who had an exacerbation compared with those who did not. In the GBT + omalizumab group, younger age at recruitment, increased eosinophil number, recent exacerbation, and higher treatment step were also associated with those who had an exacerbation. The saEPI was associated with a high negative predictive value in both groups. CONCLUSIONS: An exacerbation in children treated with GBT with or without omalizumab was associated with a higher saEPI along with higher markers of allergic inflammation, treatment step, and a recent exacerbation. Those that exacerbated on omalizumab had similar features with the exception of some markers of allergic sensitization, indicating a need to develop better markers to predict poor response to omalizumab therapy and alternative treatment strategies for children with these risk factors. The saEPI was able to reliably predict those children unlikely to have an asthma exacerbation in both groups.
Authors: Anina M Pescatore; Cristian M Dogaru; Lutz Duembgen; Michael Silverman; Erol A Gaillard; Ben D Spycher; Claudia E Kuehni Journal: J Allergy Clin Immunol Date: 2013-07-24 Impact factor: 10.793
Authors: Tmirah Haselkorn; Stanley J Szefler; F E R Simons; Robert S Zeiger; David R Mink; Bradley E Chipps; Larry Borish; Dennis A Wong Journal: Pediatr Allergy Immunol Date: 2010-12 Impact factor: 6.377
Authors: Mathew J Reeves; Sarah Lyon-Callo; Michael D Brown; Ken Rosenman; Elizabeth Wasilevich; Seymour G Williams Journal: Pediatrics Date: 2006-04 Impact factor: 7.124
Authors: Jasmina I Ivanova; Rachel Bergman; Howard G Birnbaum; Gene L Colice; Robert A Silverman; Kimmie McLaurin Journal: J Allergy Clin Immunol Date: 2012-02-11 Impact factor: 10.793
Authors: Bradley E Chipps; Stanley J Szefler; F Estelle R Simons; Tmirah Haselkorn; David R Mink; Yamo Deniz; June H Lee Journal: J Allergy Clin Immunol Date: 2007-03-30 Impact factor: 10.793
Authors: Tmirah Haselkorn; Robert S Zeiger; Bradley E Chipps; David R Mink; Stanley J Szefler; F Estelle R Simons; Marc Massanari; James E Fish Journal: J Allergy Clin Immunol Date: 2009-11 Impact factor: 10.793
Authors: Ronina A Covar; Stanley J Szefler; Robert S Zeiger; Christine A Sorkness; Mark Moss; David T Mauger; Susan J Boehmer; Robert C Strunk; Fernando D Martinez; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2008-10 Impact factor: 10.793
Authors: Timothy S Chang; Robert F Lemanske; Theresa W Guilbert; James E Gern; Michael H Coen; Michael D Evans; Ronald E Gangnon; C David Page; Daniel J Jackson Journal: J Allergy Clin Immunol Pract Date: 2013-03
Authors: Jillian H Hurst; Congwen Zhao; Haley P Hostetler; Mohsen Ghiasi Gorveh; Jason E Lang; Benjamin A Goldstein Journal: BMC Med Inform Decis Mak Date: 2022-04-22 Impact factor: 3.298
Authors: Theresa W Guilbert; Leonard B Bacharier; David T Mauger; Wanda Phipatanakul; Stanley J Szefler; Susan Boehmer; Avraham Beigelman; Anne M Fitzpatrick; Daniel J Jackson; Sachin N Baxi; Mindy Benson; Carey-Ann D Burnham; Michael D Cabana; Mario Castro; James F Chmiel; Ronina Covar; Michael Daines; Jonathan M Gaffin; Deborah A Gentile; Fernando Holguin; Elliot Israel; H William Kelly; Stephen C Lazarus; Robert F Lemanske; Ngoc Ly; Kelley Meade; Wayne Morgan; James Moy; J Tod Olin; Stephen P Peters; Jacqueline A Pongracic; Hengameh H Raissy; Kristie Ross; William J Sheehan; Christine Sorkness; W Gerald Teague; Shannon Thyne; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2019-01-17 Impact factor: 10.793
Authors: Omer Kalayci; Hanan Abdelateef; César Fireth Pozo Beltrán; Zeinab A El-Sayed; René Maximiliano Gómez; Elham Hossny; Mário Morais-Almeida; Antonio Nieto; Wanda Phipatanakul; Paulo Pitrez; Gary Wk Wong; Paraskevi Xepapadaki; Nikolaos G Papadopoulos Journal: World Allergy Organ J Date: 2019-10-03 Impact factor: 4.084
Authors: Maria Elisa Di Cicco; Maddalena Leone; Maria Scavone; Michele Miraglia Del Giudice; Amelia Licari; Marzia Duse; Ilaria Brambilla; Giorgio Ciprandi; Carlo Caffarelli; Mariangela Tosca Journal: Acta Biomed Date: 2021-11-29
Authors: Lisa Cicutto; Melanie Gleason; Christy Haas-Howard; Marty White; Jessica P Hollenbach; Shann Williams; Meghan McGinn; Miguel Villarreal; Herman Mitchell; Michelle M Cloutier; Carol Vinick; Christine Langton; Donna J Shocks; David A Stempel; Stanley J Szefler Journal: J Sch Nurs Date: 2018-10-18 Impact factor: 2.835